| All Releases |
|---|
 |
Alexion Extends Its Commitment to a Green Footprint Through Its Ambitious New Solar Energy System
Jun 19, 2009
|
11.3 KB
|
| |
CHESHIRE, Conn., Jun 19, 2009 (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) has completed the
installation of a 295 kW solar photovoltaic (PV) system at the company's
Cheshire, Conn., corporate headquarters and research facility. State
officials and other guests joined Alexion employees at yesterday's
...
|
|
|
Alexion's Soliris(R) Receives 2009 Prix Galien France for Most Innovative Drug for Rare Disease
Jun 10, 2009
|
15.8 KB
|
| |
CHESHIRE, Conn. & PARIS, Jun 10, 2009 (BUSINESS WIRE) -- Alexion Pharma France and Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN)
today received the 2009 Prix Galien France for Soliris(R)
(eculizumab) in the category of medicines for rare diseases. The award
recognizes the scientific innovation represented by the
compl...
|
|
|
Alexion to Present at the Jefferies & Co. 3rd Annual Healthcare Conference
Jun 10, 2009
|
7.1 KB
|
| |
CHESHIRE, Conn., Jun 10, 2009 (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that Dr.
Leonard Bell, Chief Executive Officer of Alexion Pharmaceuticals, will
present at the Jefferies & Co. 3rd Annual Healthcare Conference in New
York City at 10:15 a.m., ET on Wednesday, June 17, 2009.
An audi...
|
|
|
New Research Presented at EHA Congress Shows That Soliris(R) Significantly Reduced Hemolysis in Never-Transfused Patients with PNH
Jun 7, 2009
|
19.6 KB
|
| |
CHESHIRE, Conn., Jun 07, 2009 (BUSINESS WIRE) -- Clinical investigators observed that Soliris(R) (eculizumab), a
first-in-class terminal complement inhibitor developed by Alexion
Pharmaceuticals, Inc. (Nasdaq: ALXN), reduced hemolysis (red blood cell
destruction) and improved symptoms in nine patients with paroxysmal
...
|
|
|
Alexion to Present at Investor Conferences
Jun 3, 2009
|
7.5 KB
|
| |
CHESHIRE, Conn., Jun 03, 2009 (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that
management will present at three upcoming investor conferences:
Dr. Leonard Bell, Chief Executive Officer of Alexion, will present at
the Goldman Sachs 30th Annual Global Healthcare Conference in
New York City ...
|
|
|
New Study Results Verify That PNH Cells Are Found in Majority of Patients with Bone Marrow Failure Syndromes
May 29, 2009
|
16.4 KB
|
| |
CHESHIRE, Conn., May 29, 2009 (BUSINESS WIRE) -- Paroxysmal nocturnal hemoglobinuria (PNH) cells are present in the
majority of patients with myelodysplastic syndromes (MDS), aplastic
anemia (AA), and other bone marrow failure syndromes (BMF), according to
interim results from 5,285 patients enrolled in the EXPLORE trial.
...
|
|
|
Researchers to Report on the Investigational Use of Alexion's Soliris(R) (Eculizumab) to Prevent Antibody-Mediated Rejection in High-Risk Kidney Transplant Patients
May 28, 2009
|
11.7 KB
|
| |
CHESHIRE, Conn., May 28, 2009 (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that
researchers are scheduled to present early clinical and laboratory data
on the potential role of terminal complement inhibition with Soliris(R)
(eculizumab) for the treatment of a subset of kidney transplant pat...
|
|
|
Alexion Reports First Quarter 2009 Results
Apr 23, 2009
|
24.2 KB
|
| |
CHESHIRE, Conn., Apr 23, 2009 (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced financial
results for the quarter ended March 31, 2009.
First Quarter 2009 Financial Results:For the three months ended March 31, 2009, Alexion Pharmaceuticals, Inc.
("Alexion" or the "Company") reported net product sales o...
|
|
|
Alexion Pharmaceuticals to Report First Quarter 2009 Results on April 23, 2009
Apr 9, 2009
|
7.3 KB
|
| |
CHESHIRE, Conn., Apr 09, 2009 (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), today announced that the
Company will report its financial results for the first quarter ended
March 31, 2009 on Thursday, April 23, 2009 before the financial markets
open. Following the release of the financial results, Alexion ma...
|
|
|
Alexion Submits NDA in Japan for Soliris(R) (eculizumab) as a Treatment for Patients with PNH
Apr 1, 2009
|
16.0 KB
|
| |
CHESHIRE, Conn., Apr 01, 2009 (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc., (Nasdaq: ALXN) today announced that it
has submitted a New Drug Application (NDA) for Soliris? (eculizumab) as
a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH)
to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). P...
|
|
|
Alexion to Present at the 4th Annual Citi Biotech Day
Mar 25, 2009
|
7.2 KB
|
| |
CHESHIRE, Conn., Mar 25, 2009 (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that Dr.
Leonard Bell, Chief Executive Officer of Alexion Pharmaceuticals, will
present at the 4th Annual Citi Biotech Day in New York City
at 9:20 a.m. Eastern on Wednesday, April 1, 2009.
An audio webcast of Dr. B...
|
|
|
Alexion to Present at the Cowen and Company 29th Annual Health Care Conference
Mar 11, 2009
|
7.2 KB
|
| |
CHESHIRE, Conn., Mar 11, 2009 (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that Dr.
Leonard Bell, Chief Executive Officer of Alexion Pharmaceuticals, will
present at the Cowen and Company 29th Annual Health Care
Conference in Boston at 10:15 a.m. Eastern on Wednesday, March 18, 2009.
An au...
|
|
|
Alexion Joins NORD and EURORDIS in Supporting the Goals of Rare Disease Day
Feb 27, 2009
|
16.6 KB
|
| |
CHESHIRE, Conn. & PARIS, Feb 27, 2009 (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc., (Nasdaq: ALXN) has joined the National
Organization for Rare Disorders (NORD) and the European Organization for
Rare Diseases (EURORDIS) in supporting the goals of the second annual
Rare Disease Day, February 28, 2009. Rare Disease Day se...
|
|
|
Alexion's Soliris(R) (eculizumab) Receives Marketing Approval in Australia for All Patients with PNH
Feb 25, 2009
|
15.8 KB
|
| |
CHESHIRE, Conn., Feb 25, 2009 (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc., (Nasdaq:ALXN) today announced that the
Australian Government's Therapeutic Goods Administration has approved
the use of Soliris(R) (eculizumab) for the treatment of all patients in
Australia with paroxysmal nocturnal hemoglobinuria (PNH), a rare,...
|
|
|
Alexion Reports Fourth Quarter and Full Year 2008 Results
Feb 12, 2009
|
28.8 KB
|
| |
CHESHIRE, Conn., Feb 12, 2009 (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN):
-- $259 Million in Soliris(R) Sales in First Full Commercial Year ---- Continued Strong Uptake of Soliris in U.S. and Europe in Q4 ---- Soliris Research Programs Progress: Clinical Data in PNH and
Other Rare Diseases Presented at ASH and ASN --20...
|
|
|
New England Journal of Medicine Publishes Case Reports on the Investigational Use of Soliris(R) (eculizumab) in Patients with Atypical Hemolytic Uremic Syndrome (aHUS)
Jan 29, 2009
|
17.0 KB
|
| |
CHESHIRE, Conn., Jan 29, 2009 (BUSINESS WIRE) -- Two separate case reports published today in the New England Journal
of Medicine (NEJM) examine the investigational use of Soliris
(R) (eculizumab), a terminal complement inhibitor developed by
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), in patients with a rare
and s...
|
|
|
Alexion's Soliris(R) (eculizumab) Receives Marketing Approval in Canada for All Patients with PNH
Jan 29, 2009
|
15.3 KB
|
| |
CHESHIRE, Conn., Jan 29, 2009 (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc., (Nasdaq: ALXN) today announced that
Canada's national healthcare regulatory agency, Health Canada, has
approved the use of Soliris(R) (eculizumab) for the treatment of all
patients in Canada with paroxysmal nocturnal hemoglobinuria (PNH), a
...
|
|
|
Alexion Pharmaceuticals To Report Fourth Quarter and Full Year 2008 Results on February 12, 2009
Jan 12, 2009
|
7.1 KB
|
| |
CHESHIRE, Conn., Jan 12, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2008 on Thursday, February 12, 2009 before the financial markets open. Following the release of the f...
|
|
|
Soliris(R) Receives Orphan Drug Designation in Japan
Jan 12, 2009
|
14.8 KB
|
| |
CHESHIRE, Conn., Jan 12, 2009 (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today reported that
Soliris(R) (eculizumab), its first-in-class complement inhibitor, has
been designated as an orphan drug by the Ministry of Health, Labour and
Welfare of Japan. As a result of the designation, a New Drug Applicati...
|
|
|
Alexion to Present at the 27th Annual JP Morgan Healthcare Conference
Jan 5, 2009
|
6.8 KB
|
| |
CHESHIRE, Conn., Jan 05, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that Dr. Leonard Bell, Chief Executive Officer of Alexion Pharmaceuticals, will present at the 27th Annual JP Morgan Healthcare Conference in San Francisco at 4:30 p.m. local time (7:30 p.m. Eastern) on Monday...
|
|
|
